ID   REC-1
AC   CVCL_1884
SY   Rec-1; REC 1; REC1; Rec1; rec1; REC
DR   BTO; BTO:0003558
DR   CLO; CLO_0037056
DR   EFO; EFO_0002317
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-3004
DR   BioSample; SAMN01821592
DR   BioSample; SAMN01821658
DR   BioSample; SAMN03471664
DR   BioSample; SAMN10989553
DR   cancercelllines; CVCL_1884
DR   Cell_Model_Passport; SIDM01773
DR   ChEMBL-Cells; CHEMBL4482987
DR   ChEMBL-Targets; CHEMBL4483266
DR   Cosmic; 1047111
DR   Cosmic; 1086341
DR   Cosmic; 1291033
DR   Cosmic; 2088020
DR   Cosmic; 2296993
DR   Cosmic; 2756235
DR   DepMap; ACH-000068
DR   DSMZ; ACC-584
DR   DSMZCellDive; ACC-584
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM95565
DR   GEO; GSM95566
DR   GEO; GSM95570
DR   GEO; GSM104462
DR   GEO; GSM104463
DR   GEO; GSM115804
DR   GEO; GSM155072
DR   GEO; GSM155073
DR   GEO; GSM155074
DR   GEO; GSM629498
DR   GEO; GSM629499
DR   GEO; GSM887529
DR   GEO; GSM888611
DR   GEO; GSM1266771
DR   GEO; GSM1266772
DR   GEO; GSM2322622
DR   GEO; GSM3150255
DR   IARC_TP53; 25018
DR   IARC_TP53; 30218
DR   IGRhCellID; REC1
DR   IZSLER; BS TCL 227
DR   LiGeA; CCLE_530
DR   LINCS_LDP; LCL-1123
DR   PharmacoDB; REC1_1298_2019
DR   PRIDE; PXD012087
DR   Progenetix; CVCL_1884
DR   PubChem_Cell_line; CVCL_1884
DR   Wikidata; Q54949572
RX   PubMed=1572647;
RX   PubMed=7504521;
RX   PubMed=8558920;
RX   PubMed=14973505;
RX   PubMed=15126345;
RX   PubMed=16448697;
RX   PubMed=16960149;
RX   PubMed=17332242;
RX   PubMed=20215515;
RX   PubMed=21746927;
RX   PubMed=22460905;
RX   PubMed=24362935;
RX   PubMed=25315077;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25688540;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=29666304;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 38 hours (PubMed=25315077); ~38 hours (ATCC=CRL-3004); ~20-40 hours (DSMZ=ACC-584).
CC   HLA typing: A*26:01,36:04; B*35:01,57:01; C*04:01,06:02; DQA1*01:02,01:02; DRB1*04:03,04:03 (PubMed=25960936).
CC   HLA typing: A*01,03; B*35,57; C*04,06 (PubMed=25688540).
CC   HLA typing: A*01:01,24:02; B*35:01,57:01; C*04:01,06:02; DQA1*01:02,01:02; DQB1*03:02,03:02; DRB1*01:01,01:01 (PubMed=26589293).
CC   HLA typing: B*35:01:01,57:01:01; C*04:01:01,06:02:01 (DSMZCellDive=ACC-584).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16448697).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Heterozygous (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=1.88%; Native American=0%; East Asian, North=2.34%; East Asian, South=0%; South Asian=0%; European, North=48.87%; European, South=46.91% (PubMed=30894373).
CC   Caution: Wrongly indicated as originating from the lymph node of a 57 year old patient in ATCC.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; DSMZ; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 10
ST   D16S539: 11
ST   D18S51: 14,16
ST   D19S433: 14,15
ST   D21S11: 28,29
ST   D2S1338: 17
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 11,12
ST   FGA: 22,23
ST   Penta D: 9,13
ST   Penta E: 7 (PubMed=25877200)
ST   Penta E: 7,19 (DSMZ)
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   PubMed=1572647; DOI=10.1016/0888-7543(92)90303-A;
RA   Szepetowski P., Simon M.-P., Grosgeorge J., Huebner K., Bastard C.,
RA   Evans G.A., Tsujimoto Y., Birnbaum D., Theillet C., Gaudray P.;
RT   "Localization of 11q13 loci with respect to regional chromosomal
RT   breakpoints.";
RL   Genomics 12:738-744(1992).
//
RX   PubMed=7504521; DOI=10.1002/gcc.2870080204;
RA   Raynaud S.D., Bekri S., Leroux D., Grosgeorge J., Klein B.,
RA   Bastard C., Gaudray P., Simon M.-P.;
RT   "Expanded range of 11q13 breakpoints with differing patterns of cyclin
RT   D1 expression in B-cell malignancies.";
RL   Genes Chromosomes Cancer 8:80-87(1993).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=14973505; DOI=10.1038/sj.leu.2403315;
RA   Prod'homme T., Drenou B., De Ruyffelaere C., Barbieri G.,
RA   Wiszniewski W., Bastard C., Charron D., Alcaide-Loridan C.;
RT   "Defective class II transactivator expression in a B lymphoma cell
RT   line.";
RL   Leukemia 18:832-840(2004).
//
RX   PubMed=15126345; DOI=10.1158/0008-5472.CAN-03-3773;
RA   Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S.,
RA   Yoshida Y., Seto M.;
RT   "Identification and characterization of a novel gene, C13orf25, as a
RT   target for 13q31-q32 amplification in malignant lymphoma.";
RL   Cancer Res. 64:3087-3095(2004).
//
RX   PubMed=16448697; DOI=10.1016/j.leukres.2005.11.013;
RA   Camps J., Salaverria I., Garcia M.J., Prat E., Bea S., Pole J.C.M.,
RA   Hernandez L., Del Rey J., Cigudosa J.C., Bernues M., Caldas C.,
RA   Colomer D., Miro R., Campo E.;
RT   "Genomic imbalances and patterns of karyotypic variability in mantle-cell
RT   lymphoma cell lines.";
RL   Leuk. Res. 30:923-934(2006).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=17332242; DOI=10.1182/blood-2006-11-057208;
RA   Pinyol M., Bea S., Pla L., Ribrag V., Bosq J., Rosenwald A., Campo E.,
RA   Jares P.;
RT   "Inactivation of RB1 in mantle-cell lymphoma detected by
RT   nonsense-mediated mRNA decay pathway inhibition and microarray
RT   analysis.";
RL   Blood 109:5422-5429(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21746927; DOI=10.1073/pnas.1018941108;
RA   Beltran E., Fresquet V., Martinez-Useros J., Richter-Larrea J.A.,
RA   Sagardoy A., Sesma I., Almada L.L., Montes-Moreno S., Siebert R.,
RA   Gesk S., Calasanz M.J., Malumbres R., Rieger M., Prosper F.,
RA   Lossos I.S., Piris M.A., Fernandez-Zapico M.E.,
RA   Martinez-Climent J.A.;
RT   "A cyclin-D1 interaction with BAX underlies its oncogenic role and
RT   potential as a therapeutic target in mantle cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-E.C., Ruddy D., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//